GSA Capital Partners LLP Has $1.86 Million Stake in Boston Scientific Corporation $BSX

GSA Capital Partners LLP boosted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 468.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,035 shares of the medical equipment provider’s stock after purchasing an additional 15,687 shares during the period. GSA Capital Partners LLP’s holdings in Boston Scientific were worth $1,858,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in BSX. Vanguard Group Inc. boosted its stake in Boston Scientific by 0.8% in the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock worth $13,497,294,000 after purchasing an additional 1,115,337 shares in the last quarter. State Street Corp raised its position in Boston Scientific by 1.1% during the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after acquiring an additional 713,379 shares in the last quarter. Geode Capital Management LLC lifted its stake in Boston Scientific by 2.0% in the second quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock valued at $3,466,320,000 after acquiring an additional 622,602 shares during the last quarter. Norges Bank bought a new position in shares of Boston Scientific in the 2nd quarter valued at about $2,089,937,000. Finally, Invesco Ltd. increased its stake in shares of Boston Scientific by 1.4% during the 2nd quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock worth $1,810,022,000 after purchasing an additional 226,578 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Sanford C. Bernstein restated an “outperform” rating and issued a $112.00 price objective on shares of Boston Scientific in a research note on Friday, February 6th. Stifel Nicolaus dropped their price target on Boston Scientific from $125.00 to $110.00 and set a “buy” rating on the stock in a research note on Wednesday, February 4th. TD Cowen reduced their price objective on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. National Bank Financial set a $115.00 price objective on shares of Boston Scientific in a report on Monday, February 2nd. Finally, Citigroup cut their target price on shares of Boston Scientific from $130.00 to $102.00 and set a “buy” rating for the company in a research note on Thursday, February 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $109.43.

Boston Scientific Price Performance

Boston Scientific stock opened at $74.72 on Tuesday. The stock’s fifty day moving average price is $90.56 and its two-hundred day moving average price is $97.35. The firm has a market cap of $110.76 billion, a PE ratio of 38.51, a price-to-earnings-growth ratio of 1.03 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. Boston Scientific Corporation has a one year low of $72.69 and a one year high of $109.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.96% and a net margin of 14.44%.The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period in the prior year, the firm posted $0.70 EPS. Boston Scientific’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,396,580. This trade represents a 42.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.